B-cell Malignancies Clinical Trials

7 recruiting

B-cell Malignancies Trials at a Glance

16 actively recruiting trials for b-cell malignancies are listed on ClinicalTrialsFinder across 6 cities in 15 countries. The largest study group is Phase 1 with 10 trials, with the heaviest enrollment activity in Kunming, Houston, and Columbus. Lead sponsors running b-cell malignancies studies include Shenzhen Geno-Immune Medical Institute, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, and AstraZeneca.

Browse b-cell malignancies trials by phase

Treatments under study

About B-cell Malignancies Clinical Trials

Looking for clinical trials for B-cell Malignancies? There are currently 7 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new B-cell Malignancies trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about B-cell Malignancies clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 116 of 16 trials

Recruiting
Phase 1Phase 2

A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.

B-cell Malignancies
AstraZeneca174 enrolled30 locationsNCT06542250
Recruiting
Phase 2

A Study of Emavusertib + An Approved Bruton Tyrosine Kinase Inhibitor (BTKi) in Participants With Chronic Lymphocytic Leukemia (CLL) and Other B-cell Malignancies

Chronic Lymphocytic LeukemiaB-cell Malignancies
Curis, Inc.108 enrolled3 locationsNCT07271667
Recruiting
Early Phase 1

Exploratory Study on mRNA Therapeutic Drug Targeting CD19 for the Treatment of Hematologic Malignancies

B-cell Malignancies
Xinqiao Hospital of Chongqing47 enrolled1 locationNCT07349849
Recruiting
Phase 1

IASO208 Injection in the Treatment of Relapsed/Refractory B-cell Malignancies

Relapsed/Refractory B-cell Malignancies
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology12 enrolled1 locationNCT07309900
Recruiting
Not Applicable

Clinical Study Evaluating the Safety and Efficacy of BAFFR CAR-T Therapy for Relapsed/Refractory B-cell Malignancies

Relapsed/Refractory B-cell Malignancies
Donghua Zhang28 enrolled1 locationNCT07345728
Recruiting
Phase 1

Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies

Relapsed or Refractory B-cell Malignancies
Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.50 enrolled4 locationsNCT06980116
Recruiting
Phase 1

UBX-303061 in Subjects With Relapsed/Refractory B-Cell Malignancies

Relapsed/Refractory B-cell Malignancies
Ubix Therapeutics, Inc.94 enrolled11 locationsNCT06590961
Recruiting
Early Phase 1

Safety and Efficacy of ZZSW-01 in Relapsed/Refractory B-cell Malignancies

Relapsed/Refractory B-cell Malignancies
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology6 enrolled1 locationNCT07240974
Recruiting
Phase 1

A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies

Relapsed/Refractory B-cell Malignancies
Accutar Biotechnology Inc60 enrolled9 locationsNCT05780034
Recruiting
Phase 1Phase 2

A Phase I/II Multiple Center Trial of 4SCAR19 Cells in the Treatment of Relapsed and Refractory B Cell Malignancies

B-cell Malignancies
Shenzhen Geno-Immune Medical Institute200 enrolled2 locationsNCT03050190
Recruiting
Phase 1Phase 2

Combination CAR-T Cell Therapy Targeting Hematological Malignancies

B-cell Malignancies
Shenzhen Geno-Immune Medical Institute100 enrolled4 locationsNCT03125577
Recruiting
Phase 1

The LVIVO-TaVec100 Product in the Treatment of Relapsed/Refractory B-cell Malignancies

Relapsed/Refractory B-cell Malignancies
The First Affiliated Hospital with Nanjing Medical University30 enrolled6 locationsNCT07002112
Recruiting
Not Applicable

JY231(JY231) Injection for the Treatment of R/R B-cell Malignancies

B-cell Malignancies
920th Hospital of Joint Logistics Support Force of People's Liberation Army of China36 enrolled1 locationNCT07065279
Recruiting
Phase 1

Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of ICP-248 as Monotherapy or in Combination With Anti-CD20 Monoclonal Antibody in Mature B-cell Malignancies

Mature B-cell Malignancies
InnoCare Pharma Inc.78 enrolled8 locationsNCT06351527
Recruiting
Early Phase 1

UTAA09 Injection in the Treatment of Relapsed/Refractory Hematolymphatic Malignancies.

CD19-positive Relapsed or Refractory B-cell Malignancies
PersonGen BioTherapeutics (Suzhou) Co., Ltd.10 enrolled1 locationNCT06092047
Recruiting
Phase 1

Evaluation of SYS6005 in Patients With Advanced Malignant Tumor

Solid TumorsB-cell Malignancies
CSPC Megalith Biopharmaceutical Co.,Ltd.132 enrolled1 locationNCT06958679